Most Read Articles
Pearl Toh, 03 Jan 2020
Antibiotic resistance of Helicobacter (H.) pylori has more than doubled in Europe in the past two decades, raising alarm on the gravity of the issue of growing bacterial resistance to commonly-used antibiotics, a study presented at UEG Week 2019 has shown.
02 Dec 2019
Utilizing a clinical pharmacist specialist in a hepatitis C virus (HCV) treatment clinic may help improve drug therapy management of HCV-infected patients treated with direct-acting antivirals (DAAs), suggests a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
4 days ago
The use of folic acid in addition to enalapril in the treatment of patients with hypertension yields a modest increase in lifetime stroke-free survival, a study has found.

Add-on stiripentol useful for long-term treatment of refractory epilepsies

28 Nov 2019

Use of stiripentol as an adjunctive treatment in patients with different types of refractory epilepsies, including focal onset epilepsy without bilateral tonic‐clonic seizures, has demonstrated long-term efficacy in a prospective observational study.

Researchers followed 132 individuals (age, 5 months to 43 years) consecutively treated with stiripentol as an adjunctive therapy for refractory epilepsies for a median of 14.8 months. Of these patients, 30 had Dravet syndrome (DS),

Stiripentol was administered at a starting dose of 10–15 mg/kg/d, with weekly increments up to a maximum of 50 mg/kg/d based on both age and weight. Epilepsy aetiology was classified as structural, genetic, infectious, immune, metabolic and unknown.

In the cohort, 29 patients (22 percent) received more than two antiepileptic drugs. The most commonly used add-on drugs were benzodiazepines, mainly clobazam. Sixty-six patients (50 percent) achieved response, defined as a reduction in seizure frequency of ≥50 percent), and 13 of them (9.8 percent) were seizure‐free.

The rate of response was higher in the genetic aetiology group (57 percent), particularly in DS (18/30; 60 percent), and in the group of patients with refractory focal onset epilepsy without bilateral tonic‐clonic seizures (5/15; 33 percent).

Median relapse‐free survival rate was 27 months in the 66 responders. The median time to stiripentol failure was 24.6 months in the entire cohort.

More prospectively designed studies are required to confirm the efficacy of stiripentol in focal epilepsy, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 03 Jan 2020
Antibiotic resistance of Helicobacter (H.) pylori has more than doubled in Europe in the past two decades, raising alarm on the gravity of the issue of growing bacterial resistance to commonly-used antibiotics, a study presented at UEG Week 2019 has shown.
02 Dec 2019
Utilizing a clinical pharmacist specialist in a hepatitis C virus (HCV) treatment clinic may help improve drug therapy management of HCV-infected patients treated with direct-acting antivirals (DAAs), suggests a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
4 days ago
The use of folic acid in addition to enalapril in the treatment of patients with hypertension yields a modest increase in lifetime stroke-free survival, a study has found.